Suppr超能文献

应对胃癌管理中的灰色地带:伊斯坦布尔小组共识声明

Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.

作者信息

Aytaç Erman, Aslan Fatih, Çicek Bahattin, Erdamar Sibel, Gürses Bengi, Güven Koray, Falay Okan, Karahasanoğlu Tayfun, Selçukbiricik Fatih, Selek Uğur, Atalar Banu, Balık Emre, Tözün Nurdan, Rozanes İzzet, Arıcan Ali, Hamzaoğlu İsmail, Baca Bilgi, Molinas Mandel Nil, Saruç Murat, Göksel Süha, Demir Gökhan, Ağaoğlu Fulya, Yakıcıer Cengiz, Özbek Uğur, Özben Volkan, Özyar Enis, Güner Ahmet Levent, Er Özlem, Kaban Kerim, Bölükbaşı Yasemin, Buğra Dursun, Group The İstanbul

机构信息

Acıbadem Mehmet Ali Aydınlar University School of Medicine, İstanbul, Turkey.

Koç University School of Medicine, İstanbul, Turkey.

出版信息

Turk J Gastroenterol. 2019 Jul;30(7):584-598. doi: 10.5152/tjg.2018.18737.

Abstract

The geographical location and differences in tumor biology significantly change the management of gastric cancer. The prevalence of gastric cancer ranks fifth and sixth among men and women, respectively, in Turkey. The international guidelines from the Eastern and Western countries fail to manage a considerable amount of inconclusive issues in the management of gastric cancer. The uncertainties lead to significant heterogeneities in clinical practice, lack of homogeneous data collection, and subsequently, diverse outcomes. The physicians who are professionally involved in the management of gastric cancer at two institutions in Istanbul, Turkey, organized a consensus meeting to address current problems and plan feasible, logical, measurable, and collective solutions in their clinical practice for this challenging disease. The evidence-based data and current guidelines were reviewed. The gray zones in the management of gastric cancer were determined in the first session of this consensus meeting. The second session was constructed to discuss, vote, and ratify the ultimate decisions. The identification of the T stage, the esophagogastric area, imaging algorithm for proper staging and follow-up, timing and patient selection for neoadjuvant treatment, and management of advanced and metastatic disease have been accepted as the major issues in the management of gastric cancer. The recommendations are presented with the percentage of supporting votes in the results section with related data.

摘要

地理位置和肿瘤生物学差异显著改变了胃癌的治疗方式。在土耳其,胃癌的患病率在男性和女性中分别位列第五和第六。东西方国家的国际指南在胃癌治疗中未能解决大量尚无定论的问题。这些不确定性导致临床实践中存在显著的异质性,缺乏统一的数据收集,进而产生不同的治疗结果。土耳其伊斯坦布尔两家机构中专业从事胃癌治疗的医生组织了一次共识会议,以解决当前问题,并为这种具有挑战性的疾病在其临床实践中规划可行、合理、可衡量且统一的解决方案。对循证数据和现行指南进行了审查。在本次共识会议的第一阶段确定了胃癌治疗中的灰色地带。第二阶段则用于讨论、投票和批准最终决定。确定T分期、食管胃区域、合适分期及随访的影像算法、新辅助治疗的时机和患者选择,以及晚期和转移性疾病的治疗,已被视为胃癌治疗中的主要问题。结果部分将结合相关数据列出各项建议及其支持票数的百分比。

相似文献

1
2
Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study.
Cancer. 2018 Mar 15;124(6):1122-1131. doi: 10.1002/cncr.31179. Epub 2017 Dec 6.
4
Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.
Turk J Gastroenterol. 2022 Aug;33(8):627-663. doi: 10.5152/tjg.2022.211103.
6
Differences in the multimodal treatment of gastric cancer: East versus west.
J Surg Oncol. 2017 Apr;115(5):603-614. doi: 10.1002/jso.24517. Epub 2017 Feb 9.
8
Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer.
World J Surg Oncol. 2019 Jan 3;17(1):3. doi: 10.1186/s12957-018-1534-z.
9
Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer.
Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):754-761. doi: 10.1080/00365521.2017.1303845. Epub 2017 Mar 30.
10
Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
J Clin Oncol. 2015 Jun 1;33(16):1754-9. doi: 10.1200/JCO.2014.59.7765. Epub 2015 Apr 27.

引用本文的文献

1
MAM Domain Containing 2 (MAMDC2) Affects Invasion and Metastasis of Human Gastric Cancer.
Onco Targets Ther. 2025 May 26;18:679-693. doi: 10.2147/OTT.S516982. eCollection 2025.
3
Minimally invasive versus open surgery for gastric cancer in Turkish population.
Turk J Surg. 2021 Jun 30;37(2):142-150. doi: 10.47717/turkjsurg.2021.4506. eCollection 2021 Jun.
4
Current standards of surgical management of gastric cancer: an appraisal.
Langenbecks Arch Surg. 2023 Feb 6;408(1):78. doi: 10.1007/s00423-023-02789-5.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Combined treatment for gastric cancer: Immunological approach.
Turk J Gastroenterol. 2018 Mar;29(2):151-156. doi: 10.5152/tjg.2018.17398.
3
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Oncologist. 2018 Oct;23(10):1171-1177. doi: 10.1634/theoncologist.2018-0034. Epub 2018 Apr 27.
6
Polish Consensus on Treatment of Gastric Cancer; update 2017.
Pol Przegl Chir. 2017 Oct 31;89(5):59-73. doi: 10.5604/01.3001.0010.5413.
8
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验